Christopher Ogden - Dec 17, 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role: SVP, Finance and Accounting
Signature: /s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Stock symbol: CTMX
Transactions as of: Dec 17, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/19/2023, 07:58 PM
Previous filing: Mar 20, 2023
Next filing: Dec 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTMX	Common Stock	Options Exercise	$0	+6.88K	+15.71%	$0.00	50.6K	Dec 17, 2023	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTMX	Performance Stock Units (PSUs)	Options Exercise	$0	-6.88K	-50%	$0.00	6.88K	Dec 17, 2023	Common Stock	6.88K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
F2	Includes 30,466 restricted stock units.
F3	Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023.
F4	Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.